Figure 8

The number of lymphocytes and percentage of CD3⁺CD4⁺ and CD3⁺CD8⁺ cells within splenocytes (A~E) and pneumonocytes (F~J) in BCG-infecteded mice after treated intratracheally with rAd-hMASP-2. At day 21, isolated lung and spleen cells from mice were stained with PerCP-conjugated anti-CD3, PE-conjugated anti-CD4 andAPC-conjugated anti-CD8. CD3⁺CD4⁺ and CD3⁺CD8⁺ T-cell subgroup were detected via FCM, n = 5 per group. FACS analysis of T lymphocyte subsets showed no difference among various groups in total number of spleen lymphocytes (A) and CD3⁺ lymphocytes (B), percentage of CD3⁺CD4⁺ (C) and CD3⁺CD8⁺ (D) lymphocytes within splenocytes. (E) The CD3⁺ lymphocyte subsets distributed in the spleen of various groups. As compared with the rAd-EGFP group, (E) lung lymphocytes total number (2.56 × 10⁵ ± 6.41 × 10⁴) and (F) CD3⁺ lymphocytes (4.43 × 10⁴ ± 6.1 × 10³), (H) CD3⁺CD8⁺ lymphocytes percentage (24.55% ± 2.29%) in rAd-hMASP-2 group showed statistically significant increased. (J) The CD3⁺ lymphocyte subsets distributed in the lung of various groups. Data collected from five mice per group were expressed as means ± SD.